Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | HUMA | Stock Options (right to buy) | Award | $0 | +525 | +25% | $0.00 | 2.63K | Dec 19, 2024 | Common Stock | 525 | $10.28 | Direct | F1 |
Id | Content |
---|---|
F1 | On December 14, 2020, Humacyte granted options to purchase 2,625 shares of common stock, which vested as follows: (i) one-fifth on the first anniversary of the vesting commencement date, (ii) two-fifths in equal installments over a period of 24 months commencing on the first anniversary of the vesting commencement date, (iii) one-fifth upon the submission of a Biologics License Application ("BLA") to the FDA and (iv) one-fifth upon FDA approval of one of Humacyte's product candidates. Humacyte previously reported three-fifths of the option grant on a Form 4 filed on August 27, 2021 and one-fifth of the option grant on a Form 4 filed on December 12, 2023. On December 19, 2024, Humacyte received FDA approval for its acellular tissue engineered vessel product candidate for an indication in vascular trauma. Accordingly, columns 5 and 7 of Table II report the number of securities equal to the final one-fifth of the 12/14/2020 option grant. |